- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00585585
Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features
July 21, 2017 updated by: Erik Nelson, University of Cincinnati
A Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features
The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression.
Atypical depression is characterized by the ability of the person's mood to improve temporarily in response to positive events, as well as features such as increased appetite, increased sleep and severe fatigue.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
All patients will start taking 50 mg of betahistine dihydrochloride on treatment day 1 (after baseline visit).
Starting on day 4, the daily dose will be increased by adding a 50 mg dose.
If tolerated, the daily dose will be titrated to 200 mg.
At the end of week 3, the dose will be titrated to 300 mg.
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267-0559
- University of Cincinnati
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have signed written informed consent
- Be male and/or female outpatients 18 65 years of age, inclusive
- For women: must be surgically sterile, 2 years postmenopausal, or, if they have childbearing potential, using a medically accepted method of birth control and agree to continue use of this method for at least 30 days after the last dose of study drug (i.e., barrier method with spermicide, steroidal contraceptive or intrauterine device [IUD])
- Meet DSM IV1 criteria for major depressive episode (unipolar), with atypical features
- Have a score of 20 or greater on the Hamilton Depression Rating, 28-item version (HAM-D-28)
- Have a complete medical and psychiatric history, physical examination, laboratory evaluation, and ECG before study entry.
- Have baseline laboratory values and ECG that are normal, or abnormalities that are clinically insignificant
Exclusion Criteria:
- Have significant and/or unstable gastrointestinal, neurological, endocrine, cardiovascular, pulmonary, renal, hepatic, immunological or hematological disease; organic brain disease; or cancer as determined by history, physical, ECG, and laboratory examination
- Have a history of peptic ulcer disease
- Have a history of severe asthma
- Have a current diagnosis of pheochromocytoma
- Are pregnant, intending to become pregnant, nursing, at risk for pregnancy, or not practicing medically acceptable birth control. (A blood pregnancy test will be performed at the screening visit)
- Meet criteria for DSM IV1 psychoactive substance abuse or dependence in the past month
- Have a history of a psychotic disorder
- Use any medications that, in the judgment of the investigator, might have psychotropic effects, or interact unfavorably with betahistine dihydrochloride including centrally acting antihistaminic agents
- Have a history of hypersensitivity to betahistine dihydrochloride
- Exhibit, or suggestion that they may display, behavior that will not be conducive to the study procedures
- Are at significant risk of suicide as indicated by a score of 3 or greater on item number 11 on the HAM-D 28
- Have received any investigational product within 28 days of Screening
- Have used any antidepressant within 7 days of Screening (14 days for MAOIs; 21 days for fluoxetine)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1: Betahistine dihydrochloride
Oral betahistine dihydrochloride; daily dose 50-300 mg
|
oral, 50-300 mg, daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerable Dose of Betahistine Dihydrochloride in mg
Time Frame: 7 weeks
|
The highest betahistine dose that is well tolerated when patients are titrated from 50 mg to a maximum 300 mg of daily divided doses.
|
7 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Erik Nelson, MD, University of Cincinnati
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2007
Primary Completion (Actual)
January 1, 2011
Study Completion (Actual)
January 1, 2011
Study Registration Dates
First Submitted
December 28, 2007
First Submitted That Met QC Criteria
December 28, 2007
First Posted (Estimate)
January 3, 2008
Study Record Updates
Last Update Posted (Actual)
July 25, 2017
Last Update Submitted That Met QC Criteria
July 21, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Nelson #1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Major Depressive Disorder With Atypical Features
-
SunovionCompletedMajor Depressive Disorder With Mixed FeaturesUnited States, Serbia, Ukraine, Russian Federation, United Kingdom
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH)CompletedMajor Depressive Disorder With Psychotic FeaturesUnited States, Canada
-
Massachusetts General HospitalTerminatedMajor Depressive Disorder With Psychotic FeaturesUnited States
-
VA Office of Research and DevelopmentRecruitingSchizophrenia | Schizoaffective Disorder | Delusional Disorder | Major Depressive Disorder With Psychotic FeaturesUnited States
-
University of ArizonaCompletedSchizophrenia | Schizoaffective Disorder | Major Depression With Psychotic Features | Bipolar Disorder With Psychotic Features | Psychotic Disorder Not Otherwise Specified (NOS)United States
-
Rush University Medical CenterJanssen, LPTerminatedMajor Depression With Psychotic FeaturesUnited States
-
University of ArizonaTerminatedSchizophrenia | Schizoaffective Disorder | Major Depression With Psychotic Features | Psychosis Not Otherwise Specified (NOS) | Bipolar Disorder With Psychotic FeaturesUnited States
-
Duke UniversityMerck Sharp & Dohme LLCCompletedMajor Depressive Disorder Without Psychotic FeaturesUnited States
-
Max-Planck-Institute of PsychiatryCompletedSchizophrenia | Schizoaffective Disorder | Delusional Disorder | Schizotypal Disorder | Brief Psychotic Disorder | Shared Psychotic Disorder | Other Psychotic Disorder Not Due to A Substance or Known Physiological Condition | Unspecified Psychosis Not Due to a Substance or Known Physiological Condition and other conditionsGermany
-
Corcept TherapeuticsTerminatedPsychosis | Psychotic Depression | Severe Major Depression With Psychotic FeaturesUnited States
Clinical Trials on betahistine dihydrochloride
-
OBEcure Ltd.International Antiviral Therapy Evaluation CenterCompletedObesityBelgium, Germany, Netherlands
-
Abbott ProductsCompletedGait or Balance Disorder ProblemsSingapore
-
Ludwig-Maximilians - University of MunichCompletedMénière's DiseaseGermany
-
Eunice Kennedy Shriver National Institute of Child...CompletedObesity | Overnutrition | OverweightUnited States
-
P2D, Inc.National Institute of Mental Health (NIMH)CompletedAttention Deficit Disorder With HyperactivityUnited States
-
OBEcure Ltd.Completed
-
Beijing Tongren HospitalCompleted
-
Seoul National University HospitalRecruitingMeniere's DiseaseKorea, Republic of
-
Solvay PharmaceuticalsCompleted
-
Daiichi Sankyo, Inc.No longer availableAcute Myeloid Leukemia With Gene Mutations